Mark Chin - 21 Apr 2022 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role: Former Director
Signature: /s/ Mark Chin
Issuer symbol: PYXS
Transactions as of: 21 Apr 2022
Net transactions value: -$5,324,571
Form type: 4
Filing time: 25 Apr 2022, 12:12:03 UTC
Previous filing: 04 Apr 2022
Next filing: 03 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PYXS	Common Stock	Sale	$5,324,571	-1,745,761	-100%	$3.05	0	21 Apr 2022	See footnote	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Mark Chin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The securities were held directly by Arix Bioscience Holdings Limited ("Arix"). The Reporting Person is one of for members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

Content

The securities were held directly by Arix Bioscience Holdings Limited ("Arix"). The Reporting Person is one of for members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.